LeafNLP Demos
Back to explore

Report #2889521

Received Mar 18, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
ID
Recovered
Unknown
Vaccinated
Apr 1, 2025
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.2Unknown—

Symptoms (1)

Incomplete course of vaccination

Symptom narrative

The patient took only two doses of Vivotif; Case reference number US-BN-2025-001375 is a spontaneous case initially received from other healthcare professional via Communication (reference number: USBAV25-1955) on 07-Aug-2025 and concerns a 35-year-old, male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified dates also reported as in Apr-2025, the patient took first and second dose of Vivotif (batch number: unknown) at an unknown dose, route, or site of administration for an unknown indication. The patient did not take any further doses (explicitly coded as ‘incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 35-year-old, male patient took first and second dose of Vivotif, at an unknown dose, route, or site of administration for an unknown indication however did not take any further doses which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 35-year-old, male patient took first and second dose of Vivotif, at an unknown dose, route, or site of administration for an unknown indication however did not take any further doses which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect product but to human factor. The case is non-serious.

Medical history

Comments: NONE